Roundtable on Translating Genomic-Based Research for Health 2011 Annual Report (2012) / Chapter Skim
Currently Skimming:
Roundtable on Translating Genomic-Based Research for Health: 2011 Annual Report
Roundtable on Translating Genomic-Based Research for Health: 2011 Annual Report
Pages 1-12
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 1... ...
BOARD ON HEALTH SCIENCES POLICY Roundtable on Translating Genomic-Based Research for Health 2011 Annual Report
|
From page 2... ...
Specific issues and agenda topics are determined by the Roundtable membership and span a broad range of issues relevant to the translation process. For more information about the Roundtable on Translating Genomic-Based Research for Health, please visit our website at www.iom.edu/genomicroundtable or call Adam Berger at (202)
|
From page 3... ...
During this past year, the Roundtable sponsored workshops and meetings addressing several critical areas in the translation of genomics findings, including the potential risks and benefits of whole genome sequencing in clinical care; clarifying regulatory and reimbursement pathways for genomic tests; and the potential for genomic tools to enhance drug discovery. Each activity brought together diverse stakeholder views and explored controversies and common ground as well as potential solutions for advancing the field.
|
From page 4... ...
Integrating Large-Scale Genomic Information into Clinical Practice: A Workshop (July 19, 2011) As DNA sequencing technology becomes more refined, costs continue to drop, and clinical applications increase for genomic and genetic analyses, the integration of this new technology into practice is inevitable.
|
From page 5... ...
The sequencing of the human genome and the identification of links between specific genetic variants and disease formation have led to an explosion of genome-based diag nostic tests that have the potential to direct therapeutic interventions or predict the onset of disease. However, the current adoption of genomic diagnostic tests into prac tice by providers has been limited due to a lack of evidence of clinical utility.
|
From page 6... ...
There are many suspected causes for this trend, including increased regulatory barriers, the rising costs of scientific inquiry, and the lack of production models that have successfully incorporated new technology. Regardless of the cause, this trajectory is not economically sustainable, and in response many companies are turning toward collaborative models of drug development.
|
From page 7... ...
The presentations and discussions will explore various aspects of the issue, including target identification, clinical trial design, strategic partnerships, and the use of emerging technologies, such as next generation sequencing. The workshop will also investigate the economic drivers, incentives, and models that use genomics in drug development and will feature an array of stakeholders, including leaders from academia, industry, and governmental organizations.
|
From page 8... ...
May 24 Challenges and Opportunities November 17 in Using Newborn Screening Generating Evidence for Samples for Translational July 23 Genomic Diagnostic Test February 22-23 Research Workshop; Meeting 10 Meeting 11 Development Workshop Meeting 13 2011 July 22 November 18 Establishing Precompetitive Collaborations to Stimulate Meeting 12 Genomics-Driven Drug Development Workshop
|
From page 9... ...
The group is currently planning a workshop to investigate the economic drivers, incentives, and models that use genomics in drug development. Diagnostic Applications The Roundtable established the Diagnostic Generating Evidence for Applications working group to discuss issues related to Genomic Diagnostic Test Development: Workshop the development and use of molecular diagnostics.
|
From page 10... ...
Genetic Alliance March 21 New Paradigms in Drug Discovery: December 3 How Genomic Data Are Being Used July 17-18 Improving the Efficiency and to Revolutionize the Drug Discovery Assessing the Economics of Effectiveness of Genomic Science and Development Process Workshop Genomic Medicine Workshop Translation Workshop 2013 March 22 July 18 December 4 Meeting 16 Meeting 17 Meeting 18
|
From page 11... ...
Roundtable Sponsors Roundtable Members and Sponsorship American College of Medical Genetics and Genomics American Medical Association American Nurses Association Blue Cross and Blue Shield Association Centers for Disease Control and Prevention College of American Pathologists Department of the Air Force Department of Veterans Affairs Eli Lilly and Company Genetic Alliance Health Resources and Services Administration Johnson & Johnson Kaiser Permanente/East Bay Community Foundation Life Technologies Corporation National Cancer Institute National Coalition for Health Professional Education in Genetics National Heart, Lung, and Blood Institute National Human Genome Research Institute National Institute of Mental Health National Institute on Aging National Society of Genetic Counselors Office of Rare Diseases Research Patient Advocacy Pfizer Inc. Foundations and 4% Associations 26% 44% Government 22% 4% Industry Miscellaneous Nonprofit
|
From page 12... ...
The Institute of Medicine serves as adviser to the nation to improve health. Established in 1970 under the charter of the National Academy of Sciences, the Institute of Medicine provides independent, objective, evidence-based advice to policy makers, health professionals, the private sector, and the public.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.